Last updated on July 2019

A Study of TAS-120 in Patients With Advanced Solid Tumors


Brief description of study

This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.

The study will be conducted in 3 parts, (1) Dose escalation to determine the MTD and/ or RP2D of TAS-120 in which this part of the study has been completed; (2) Phase 1 expansion to further evaluate the safety and efficacy of RP2D of TAS-120 in patients with tumors harboring specific FGFR aberrations, specifically in patients with cholangiocarcinoma, gliomas , urothelial carcinomas and any other tumors with FGFR fusion or activating mutation or amplification. Up to approximately 185 patients will be enrolled in the phase 1 expansion; and (3) Phase 2 study to confirm ORR of TAS-120 in intra-hepatic CCA patients with tumors harboring FGFR2 gene fusions. Approx. 100 patients will be enrolled in phase 2.

Detailed Study Description

Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017

Phase 1 Dose Expansion: (CLOSED)

Up to approximately 185 patients will be enrolled among the 8 groups as outlined below:

  • Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions.
  • Group 2- CCA (iCCA or eCCA) with FGFR2 gene fusions that are chemotherapy naive or intolerant to first line chemotherapy (i.e., on chemotherapy regimen 1 cycle).
  • Group 3 - CCA (iCCA or eCCA) with FGFR2 gene fusions treated with prior FGFR inhibitors.
  • Group 4 - CCA (iCCA or eCCA) with other FGFR2 abnormalities, ie, gene mutations, rearrangements or amplifications.
  • Group 5 - GBM or grade III glioma (i.e, anaplastic astrocytoma or anaplastic oliogodendroglioma) with FGFR gene fusions or activating mutations
  • Group 6 - Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations.
  • Group 7: Basket of tumor types with tumors harboring FGFR2 amplification (10 copies).
  • Group 8 - Basket of tumor types (except CCA, brain tumors and advanced urothelial carcinomas) with tumors harboring FGFR gene fusions or activating mutations.

Phase 2:

Approximately 100 iCCA patients with confirmed FGFR2 gene fusions will be treated. Patients will be centrally screened for FGFR2 gene fusions. This is a Single arm study with the primary endpoint of ORR.

Clinical Study Identifier: NCT02052778

Find a site near you

Start Over

Mayo Clinic (Jacksonville)

Jacksonville, FL United States
  Connect »

ASAN Medical Center (Seoul)

Seoul, Korea, Republic of
  Connect »

UW Carbone Cancer Center

Madison, WI United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Mayo Clinic (AZ)

Scottsdale, AZ United States
  Connect »

Mayo Clinic (MN)

Rochester, MN United States
  Connect »

UCSF - Helen Diller

San Francisco, CA United States
  Connect »

New Mexico Cancer Care Alliance

Albuquerque, NM United States
  Connect »

Spartanburg Medical Center

Spartanburg, SC United States
  Connect »

Florida Hospital

Orlando, FL United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Greenville Health System ITOR

Greenville, SC United States
  Connect »

Mary Crowley

Dallas, TX United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »